{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:00:26Z","timestamp":1791216026530,"version":"4.1.0"},"reference-count":28,"publisher":"BMJ","issue":"15","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2024,4,10]]},"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Enzyme replacement therapy (ERT) may halt or attenuate disease progression in patients with Anderson-Fabry disease (AFD). However, whether left ventricular hypertrophy (LVH) can be prevented by early therapy or may still progress despite ERT over a long-term follow-up is still unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Consecutive patients with AFD from the Independent Swiss-Fabry Cohort receiving ERT who were at least followed up for 5 years were included. Cardiac progression was defined as an increase of &gt;10\u2009g\/m<jats:sup>2<\/jats:sup> in left ventricular mass index (LVMI) between the first and the last available follow-up transthoracic echocardiography.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>60 patients (35 (23\u201348) years, 39 (65%) men) were followed up for 10.5 (7.2\u201312.2) years. 22 had LVH at ERT start (LVMI of 150\u00b138\u2009g\/m<jats:sup>2<\/jats:sup>). During follow-up, 22 (36%, 34\u00b115 years) had LVMI progression of 12.1 (7\u201317.6) g\/m<jats:sup>2<\/jats:sup> per 100 patient-years, of these 7 (11%, 29\u00b113 years) with no LVH at baseline. Three of them progressed to LVH. LVMI progression occurred mostly in men (17 of 39 (43%) vs 5 of 21 (24%), p&lt;0.01) and after the age of 30 years (17 of 22 (77%)). LVH at ERT start was associated with LVMI progression (OR 1.3, 95%\u2009CI 1.1 to 2.6; p=0.02). A total of 19 (31%) patients experienced a major AFD-related event. They were predominantly men (17 of 19, 89%), older (45\u00b111 vs 32\u00b19 years) with baseline LVH (12 of 19, 63%), and 10 of 19 (52%) presented with LVMI progression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Over a median follow-up of &gt;10 years under ERT, 36% of the patients still had LVMI cardiac progression, and 32%, predominantly older men, experienced major AFD-related events. LVH at treatment initiation was a strong predictor of LVMI progression and adverse events on ERT.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/heartjnl-2024-323975","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T13:15:54Z","timestamp":1715778954000},"page":"997-1004","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Fabry disease: development and progression of left ventricular hypertrophy despite long-term enzyme replacement therapy"],"prefix":"10.1136","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5819-204X","authenticated-orcid":false,"given":"Niccolo","family":"Maurizi","sequence":"first","affiliation":[{"name":"Department of Cardiology, University Hospital of Lausannne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albina","family":"Nowak","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Gruner","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5779-7431","authenticated-orcid":false,"given":"Mehdi","family":"Namdar","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hopitaux Universitaires de Gen\u00e8ve, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schmied","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra Pia","family":"Porretta","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital of Lausannne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Barbey","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital of Lausannne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Monzambani","sequence":"additional","affiliation":[{"name":"Department of Immunology and Allergy, Lausanne University Hospital, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3083-7333","authenticated-orcid":false,"given":"Pierre","family":"Monney","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital of Lausannne, Lausanne, Switzerland"},{"name":"University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Barbey","sequence":"additional","affiliation":[{"name":"Department of Immunology and Allergy, Lausanne University Hospital, Lausanne, Switzerland"},{"name":"University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"2025100708190100000_110.15.997.1","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","article-title":"Cardiac involvement in Fabry disease: JACC review topic of the week","volume":"77","author":"Pieroni","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025100708190100000_110.15.997.2","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"2025100708190100000_110.15.997.3","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.38.11.769"},{"key":"2025100708190100000_110.15.997.4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094434","article-title":"Fabry disease and the heart: A comprehensive review","volume":"22","author":"Azevedo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025100708190100000_110.15.997.5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.21.2743"},{"key":"2025100708190100000_110.15.997.6","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/ejhf.1960","article-title":"An expert consensus document on the management of cardiovascular manifestations of Fabry disease","volume":"22","author":"Linhart","year":"2020","journal-title":"European J of Heart Fail"},{"key":"2025100708190100000_110.15.997.7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ymgme.2018.04.008","article-title":"The beneficial effects of long-term enzyme replacement therapy on cardiac involvement in Japanese Fabry patients","volume":"124","author":"Hongo","year":"2018","journal-title":"Mol Genet Metab"},{"key":"2025100708190100000_110.15.997.8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.794529"},{"key":"2025100708190100000_110.15.997.9","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2015-308897"},{"key":"2025100708190100000_110.15.997.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.09.008"},{"key":"2025100708190100000_110.15.997.11","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2013.53"},{"key":"2025100708190100000_110.15.997.12","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/ehjci\/jex244","article-title":"EACVI scientific documents committee. standardization of adult transthoracic echocardiography reporting in agreement with recent chamber Quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of cardiovascular imaging","volume":"18","author":"Galderisi","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2025100708190100000_110.15.997.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2018.06.004"},{"key":"2025100708190100000_110.15.997.14","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jev014"},{"key":"2025100708190100000_110.15.997.15","doi-asserted-by":"publisher","DOI":"10.3109\/10976640009148691"},{"key":"2025100708190100000_110.15.997.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(02)02381-0"},{"key":"2025100708190100000_110.15.997.17","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00675.x"},{"key":"2025100708190100000_110.15.997.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107053450102"},{"key":"2025100708190100000_110.15.997.19","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e3181bb05bb"},{"key":"2025100708190100000_110.15.997.20","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2006.104026"},{"key":"2025100708190100000_110.15.997.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2011.03.022"},{"key":"2025100708190100000_110.15.997.22","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2014-102797"},{"key":"2025100708190100000_110.15.997.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2012.05.011"},{"key":"2025100708190100000_110.15.997.24","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/jhg.2016.78","article-title":"Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes","volume":"61","author":"Kim","year":"2016","journal-title":"J Hum Genet"},{"key":"2025100708190100000_110.15.997.25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2004.01424.x"},{"key":"2025100708190100000_110.15.997.26","doi-asserted-by":"publisher","DOI":"10.1111\/cge.12613"},{"key":"2025100708190100000_110.15.997.27","doi-asserted-by":"crossref","first-page":"f153","DOI":"10.1093\/europace\/eux261","article-title":"Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice","volume":"20","author":"Baig","year":"2018","journal-title":"Europace"},{"key":"2025100708190100000_110.15.997.28","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.118.008424","article-title":"Predictors of clinical evolution in Prehypertrophic Fabry disease","volume":"12","author":"Camporeale","year":"2019","journal-title":"Circ Cardiovasc Imaging"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2024-323975","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T15:39:32Z","timestamp":1759851572000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2024-323975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":28,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2024,7,10]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1136\/heartjnl-2024-323975"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2024-323975","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,15]]}}}